Alnylam Pharmaceuticals posted second-quarter revenue of $773.7 million, outpacing analysts’ estimates as its RNA-interference drug Amvuttra generated $492 million, more than doubling from a year earlier. About 1,400 cardiomyopathy patients were on the treatment by the end of June, helping lift total transthyretin franchise sales 77 percent year on year. Adjusted earnings came in at $0.32 a share, compared with a consensus forecast for a $0.79 loss. Buoyed by the strong launch, the Cambridge, Massachusetts-based company raised its 2025 total-net-product-revenue target to $2.65 billion–$2.8 billion, a midpoint increase of 27 percent, and now sees sales of its TTR drugs reaching up to $2.28 billion. The stock climbed roughly 15 percent to a 52-week high after the results. Regeneron Pharmaceuticals reported revenue of $3.68 billion for the same period, a 4 percent increase, with adjusted earnings of $12.89 a share. U.S. sales of high-dose Eylea rose 29 percent to $393 million, offsetting a continued decline in the original formulation. Partner-recorded global Dupixent sales grew 22 percent to $4.34 billion. The quarter was clouded by a new FDA complete response letter for the company’s experimental lymphoma antibody odronextamab, stemming from manufacturing issues at a recently acquired Novo Nordisk facility in Indiana, and Regeneron cautioned that pending high-dose Eylea filings could also be delayed.